Downloaded from http://aac.asm.org/ on June 26, 2018 by University of East Anglia

# © Crown copyright 2018.

The government of Australia, Canada, or the UK ("the Crown") owns the copyright interests of authors who are government employees. The Crown Copyright is not transferable.

1	
2	Activity of RX-04 pyrrolocytosine protein synthesis
3	inhibitors against multiresistant Gram-negative bacteria
4	
5	<sup>1</sup> ANNA VICKERS, <sup>1</sup> SHAZAD MUSHTAQ, <sup>1</sup> NEIL WOODFORD, <sup>1</sup> MICHEL DOUMITH
6	<sup>1,2</sup> DAVID M LIVERMORE*
7	
8	<sup>1</sup> Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI)
9	Reference Unit, National Infection Service, Public Health England, London, United
10	Kingdom; <sup>2</sup> Norwich Medical School, University of East Anglia, Norwich, Norfolk,
11	United Kingdom
12	
13	
14	
15	
16	
17	
18	
19	
20	*Corresponding author:
21 22 23 24 25 26	Floor 2, Bob Champion Research & Educational Building, James Watson Road, University of East Anglia, Norwich Research Park, NORWICH, NR4 7UQ
27 28 29	Tel: +44(0)1603-597-568 e-mail: d.livermore@uea.ac.uk

Pyrrolocytosines RX-04A-D are designed to bind to the bacterial 50S ribosomal 30 subunit differently from currently-used antibiotics. The four analogs had 31 broad anti-Gram-negative activity: RX-04A inhibited 94.7% of clinical 32 Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa 33 at 0.5-4 µg/ml, with no MICs >8 µg/ml. MICs for multi-resistant carbapenemase 34 producers were up to two-fold higher than for control strains, with values >8 35 µg/ml for one Serratia isolate with porin and efflux lesions. mcr-1 did not 36 affect MICs. 37

38

One approach in the search for new antibacterial agents is to model the target interactions of natural antibiotics that are unsuitable for pharmaceutical development, owing to toxicity or instability, and to use this information to design synthetic molecules that achieve similar binding without the unfavorable traits of the original compounds.

44 Melinta Pharmaceuticals has applied this strategy to blasticidin S, a natural product of Streptomyces griseochromogenes that inhibits both eukaryotic and 45 46 prokaryotic ribosomes but which has proved useful only as a fungicide, deployed to 47 control rice blast disease in Japan [1]. Modelling of the ribosomal interactions of blasticidin [2], TAB-1057A/B [3] and amecitin [4] - which have overlapping targets 48 that are distinct from those of clinically-used bacterial protein synthesis inhibitors -49 50 had led to several new antibacterial scaffolds, including pyrrolocytosines [5,6]. These are chemically unrelated to blasticidin, but mimic its principal interactions with the 51 bacterial 50S subunit [6]. In-vitro antibacterial activity indicates that the 52 53 pyrrolocytosines penetrate into bacterial cells, and further development has sought to optimise this penetration for Gram-negative bacteria whilst reducing vulnerability 54

to efflux [5]. Chemical properties of the pyrrolocytosine derivatives along with
 synthetic methods, are outlined in the relevant patents [7-9].

We evaluated four pyrrolocytosine derivatives, RX-04A - D (fig. 1), against a 57 96 Gram-negative clinical isolates, biased to over-represent panel of 58 carbapenemase producers, Enterobacteriaceae with mcr-1 and Pseudomonas 59 aeruginosa with up-regulated efflux. We additionally tested Escherichia coli HB10B 60 and its transformant, carrying plasmid p594, which encodes expression of mcr-1 61 [10]. The mcr-1 and carbapenemase genes were detected by PCR or sequencing 62 [10,11] whilst efflux levels in P. aeruginosa isolates were inferred by interpretive 63 reading of antibiograms data, which predicts mechanisms from phenotypes [12]. 64 MICs of the four RX-04 analogs and comparators (amikacin, cefepime, colistin, 65 meropenem, and tigecycline) were determined by CLSI broth microdilution [13] using 66 pre-prepared plates (Trek Diagnostic Systems, Thermofisher, Oakwood, OH). DNA 67 from four Serratia isolates differing in susceptibility to the pyrrolocytosines was 68 extracted using a QIAsymphony automated instrument. Sequencing libraries were 69 prepared using the Nextera XT DNA library preparation kit and sequenced on 70 Illumina HiSeq 2500 system using the 2 x 100-bp paired-end mode. Genomes were 71 assembled de with VelvetOptimiser 2.1.9 72 novo software (http://bioinformatics.net.au/software.velvetoptimiser.shtml) and then compared with 73 each other to seek genetic modifications that were specific to the Serratia with the 74 highest pyrrolocytosine MICs, particularly in genes encoding porins, efflux pumps 75 and the rRNA targets of the pyrrolocytosines. 76

Downloaded from http://aac.asm.org/ on June 26, 2018 by University of East Anglia

MICs by species, irrespective of resistance mechanism, are shown in Table 1,
whilst Table 2 shows geometric mean MICs for major resistance types represented
in the test panels. Non-susceptibility rates to comparators for the *Enterobacteriaceae*

isolates (n=66), at CLSI breakpoints, were: amikacin 14%, cefepime 50%, colistin 33% (2  $\mu$ g/ml EUCAST breakpoint), meropenem 47%, and tigecycline 15% (1  $\mu$ g/ml EUCAST breakpoint); those for the same agents against the *A. baumannii* isolates (n=10) were amikacin 40%, cefepime 50%, colistin 0%, meropenem 50% and tigecycline 50%, respectively. Non-susceptibility rates for the *P. aeruginosa* isolates (n=20) were amikacin 15%, cefepime 45%, colistin 25% and meropenem, 45%.

Despite this heavy loading with isolates resistant to established agents, MIC distributions of RX-04A - D were all unimodal and tightly clustered. MICs were lowest for RX-04A, where 94.7% of values, for all species pooled, lay between 0.5 and 4  $\mu$ g/ml, with no values greater than 8  $\mu$ g/ml. MICs were highest for analogs RX-04C and RX-04D, particularly for *P. aeruginosa*. Irrespective of the analog, the general pattern was for MICs to be lowest for *E. coli*, slightly higher for other *Enterobacteriaceae*, particularly *Serratia* spp., and highest for *P. aeruginosa*. Downloaded from http://aac.asm.org/ on June 26, 2018 by University of East Anglia

MICs for a single S. marcescens isolate, which also had OXA-48 93 94 carbapenemase, were raised markedly, at 8, 16, >16 and >16  $\mu$ g/ml for molecules RX-04A, B, C and D respectively, compared with 1-2, 1-4, 2-4 and 2-4 µg/ml, 95 96 respectively, for the remaining three Serratia isolates tested. Comparison of the four sequenced genomes revealed the high-MIC isolate to have both (i) a premature stop 97 98 codon (Tyr211) in omp2, which is an ompC/F homolog and (ii) multiple unique 99 changes (as compared with all three low-MIC Serratia isolates) in the sdeCDE operon, encoding an RND pump system [14], specifically, Asn407Ser, Ser432Asn, 100 101 Glu433Ala, Ala437Thr, Ala438Asn, Asn439Lys, Ala440Thr, Glu443Gln, ArgR448Gly in sdeC, Glu111Asp and Thr363Met in sdeD and Glu240Asp in sdeE. None of these 102 changes were observed in the three low-MIC Serratia genomes. No lesions specific 103 104 to the high-MIC isolate were found (i) in other recognised porin genes (omp1 and

Antimicrobial Agents and

Chemotherapy

omp3), (ii) in porin regulatory genes (ompR and envZ), (iii) in efflux pump genes (smdAB, sdeXY, smfY and ssmE), nor (iv) in genes encoding the 16S or 23S rRNA targets of the RX-04A-D molecules. Inactivation of omp2 seems likely to reduce pyrrolocytosine uptake and the sdeCDE lesions may increase efflux explaining the phenotype of the high-MIC Serratia isolate. These uptake and efflux lesions also are congruent with an observed meropenem MIC of 32  $\mu$ g/ml, which is unusually high for an Enterobacteriaceae with an OXA-48 β-lactamase.

Geometric mean MICs of the four analogs for carbapenemase-producing 112 113 Enterobacteriaceae were slightly above those for the susceptible control strains, though the differentials never exceeded one doubling dilution (Table 2). These small 114 rises again probably reflected widespread reductions in permeability or upregulations 115 116 in efflux among the carbapenemase-producing Enterobacteriaceae. The MIC differential for carbapenemase-producing versus non-producing A. baumannii was 117 larger, exceeding two-fold for analogs RX-04B-D, though not for RX-04A; however, 118 119 numbers were small and 3/5 OXA-23-producing isolates belonged to the same 120 lineage (International Clone II [15]) raising the possibility that the mean was skewed 121 by over-representation of this lineage.

The effect of *mcr-1* was of interest because the pyrrolocytosines are polybasic 122 123 (fig. 1), raising the hypothetical concern that MCR-1-mediated substitution of lipopolysaccharides with positively-charged phosphoethanolamine [16] might impede 124 their initial interaction with the cell surface, reducing uptake. MICs of the RX analogs 125 126 for the mcr-1-positive isolates were around one doubling dilution above those for control strains. However most (11/14) of these isolates were Salmonella enterica, 127 being compared with E. coli controls, and the differential may reflect species rather 128 129 than mechanism. Crucially, transformation of E. coli DH10B with the mcr-1-

encoding plasmid p594 had no effect on MICs of RX-04A, B, C and D, which 130 remained at 0.25, 0.5, 0.5 and 1 µg/ml respectively, whereas the MIC of colistin was 131 raised from 0.25 to 4  $\mu$ g/ml. A caveat is that we do not know the extent of LPS 132 modification achieved by p594-mediated carriage of mcr-1, nor the mode of 133 expression, meaning that we cannot definitively exclude the possibility that induction 134 135 by the pyrrolocytosines was weaker than by colistin. This seems unlikely, though: if LPS-substitution with positively charged alcohols and sugars compromised the 136 pyrrolocytosines, then generalized resistance would be expected in colistin-resistant 137 138 genera such as Serratia, and this was not seen.

In the case of *P. aeruginosa*, geometric mean MICs of all analogs were ca. 139 1.5-fold higher for the isolates with 'normal' versus low efflux, but did not rise further 140 141 for those with elevated efflux-mediated resistance to  $\beta$ -lactams and fluoroquinolones (Table 2). 142

In conclusion, these data indicate that the four pyrrolocytosine molecules had 143 144 broad activity against Enterobacteriaceae and non-fermenters, with RX-04A the most active analog. Near-full activity was retained against isolates with resistance 145 mechanisms of current concern, including against carbapenemase producers, those 146 147 with mcr-1-mediated colistin resistance and (perhaps most surprisingly) P. aeruginosa with up-regulated efflux. A caveat is that the strain panel was small and 148 we cannot exclude the possibility that resistance might arise from novel or 149 unsuspected mechanisms, only detectable with a larger panel. Notably, raised 150 MICs were seen for one Serratia with inactivated omp2 and upregulated sdeCDE 151 efflux suggesting that combinations of impermeability and up-regulated efflux can 152 compromise activity, at least against this species. 153

nemotherapv

Antimicrobial Agents and

Chemotherapy

Given this spectrum, the new target, and demonstrable activity in experimental infections [17], the pyrrolocytosine class warrants further evaluation with a view to possible clinical development.

157

158 FUNDING

159 This study was funded by Melinta Therapeutics, Inc.

160 161

## 162 Transparency declaration

163 DML: Advisory Boards or ad-hoc consultancy Accelerate, Achaogen, Adenium, Allecra, AstraZeneca, Auspherix, Basilea, BioVersys, Centauri, Discuva, Integra-Holdings, Meiji, 164 165 Melinta, Nordic, Pfizer, Roche, Shionogi, Taxis, T.A.Z., Tetraphase, The Medicines 166 Company, VenatoRx, Wockhardt, Zambon, Zealand. Paid lectures – Astellas, AstraZeneca, bioMerieux, Beckman Coulter, Cardiome, Cepheid, Merck, Pfizer, and Nordic. Relevant 167 shareholdings- Dechra, GSK, Merck, Perkin Elmer, Pfizer amounting to <10% of portfolio 168 169 value. Other authors: no personal items to declare; however, PHE's AMRHAI Reference 170 Unit has received financial support for conference attendance, lectures, research projects or 171 contracted evaluations from numerous sources, including: Accelerate Diagnostics, 172 Achaogen Inc, Allecra Therapeutics, Amplex, AstraZeneca UK Ltd, AusDiagnostics, Basilea 173 Pharmaceutica, Becton Dickinson Diagnostics, bioMérieux, Bio-Rad Laboratories, The 174 BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, European Centre for Disease Prevention and Control, Food Standards Agency, 175 176 GlaxoSmithKline Services Ltd, Helperby Therapeutics, Henry Stewart Talks, IHMA Ltd, 177 Innovate UK, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp, 178 Meiji Seika Pharma Co., Ltd, Mobidiag, Momentum Biosciences Ltd, Neem Biotech, NIHR, 179 Nordic Pharma Ltd, Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd, Roche, 180 Rokitan Ltd, Smith & Nephew UK Ltd, Shionogi & Co. Ltd, Trius Therapeutics, VenatoRx 181 Pharmaceuticals, Wockhardt Ltd., and the World Health Organization.

Antimicrobial Agents and

Chemotherapy

## 182 References

- 183 1. Misato T, Ko K and Yamaguchi I. 1977. Use of antibiotics in agriculture, p 53-88. *In* 184 Perlan D (ed), Advances in Applied Microbiology Vol 21. Academic Press NY
- Svidritskiy E, Ling C, Ermolenko DN, Korostelev AA. 2013. Blasticidin S inhibits translation by trapping deformed tRNA on the ribosome. Proc Natl Acad Sci USA110:12283-8.
- Xu L, Zhang L, Jones R, Bryant C, Boddeker N, Mabery E, Bahador G, Watson J, Clough J, Arimilli M, Gillette W, Colagiovanni D, Wang K, Gibbs C, Kim CU. 2011.
   SAR studies on dihydropyrimidinone antibiotics. Bioorg Med Chem Lett 21:1670-1674
- Donarski J, Shammas C, Banks R, Ramesh V. 2006. NMR and molecular modelling studies of the binding of amicetin antibiotic to conserved secondary structural motifs of 23S ribosomal RNAs. J Antibiot (Tokyo) 59:177-183.
- Duffy E, Devivo M, Kanyo Z, Bhattacharjee. 2011. The molecular tuning of RX-04, a novel broad spectrum antibacterial class for coverage of MDR gram-negative pathogens. Abstr 51st Intersci Conf Antimicrob Agents Chemother abstr FI-1843. Available via http://melinta.com/wp-content/uploads/2015/08//Rib-X\_RX-04\_ICAAC-2011\_F1-1843\_092011.pdf
- Kanyo Z, Devivo M, Bhattacharjee A, Ippolito J, Wimberly B, Duffy E. 2011.
   Structural basis for the binding of RX-04, a novel brad spectrum antibacterial class to bacterial ribosomes. Abstr 51st Intersci Conf Antimicrob Agents Chemother abstr FI-1842. Available via http://melinta.com/wp-content/uploads/2015/08//Rib-X\_RX-04\_ICAAC-2011\_F1-1842\_092011.pdf
- Melinta Pharmaceuticals, Kanyo ZF, Bhattacharjee A, Marr A, Duffy EM. 2015.
   Animicrobials and methods of making and using same. WO/2015/035426 United
   States
- Melinta Pharmaceuticals, Duffy EM, Bhattacharjee A, Kanyo ZF, Ippolito JA. 2017.
   Animicrobials and methods of making and using same. WO/2017/193016. United
   States
- Melinta Pharmaceuticals, Duffy EM, Bhattacharjee A, Kanyo ZF, Ippolito JA. 2017.
   Animicrobials and methods of making and using same. WO/2017/193017. United
   States
- 10. Doumith M, Godbole G, Ashton P, Larkin L, Dallman T, Day M, Day M, MullerPebody B, Ellington MJ, de Pinna E, Johnson AP, Hopkins KL, Woodford N. 2016.
  Detection of the plasmid-mediated *mcr-1* gene conferring colistin resistance in
  human and food isolates of *Salmonella enterica* and *Escherichia coli* in England and
  Wales. J Antimicrob Chemother 71:2300-2305.
- Ellington MJ, Findlay J, Hopkins KL, Meunier D, Alvarez-Buylla A, Horner C, McEwan A, Guiver M, McCrae LX, Woodford N, Hawkey P. 2016. Multicentre evaluation of a real-time PCR assay to detect genes encoding clinically relevant carbapenemases in cultured bacteria. Int J Antimicrob Agents 47:151-154

223	<ol> <li>Livermore DM, Winstanley TG, Shannon KP. 2001. Interpretative reading:</li></ol>
224	recognizing the unusual and inferring resistance mechanisms from resistance
225	phenotypes. J Antimicrob Chemother 48 Suppl 1:87-102
226	<ol> <li>Clinical and Laboratory Standards Institute. 2015. Methods for Dilution Antimicrobial</li></ol>
227	Susceptibility Tests for Bacteria That Grow Aerobically-Tenth Edition: Approved
228	Standard M7-A10. CLSI, Wayne, PA, USA
229	<ol> <li>Kumar A, Worobec EA. 2005. Cloning, sequencing, and characterization of the</li></ol>
230	SdeAB multidrug efflux pump of Serratia marcescens. Antimicrob Agents Chemother
231	49:1495-1501.
232	<ol> <li>Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gram-negative bacteria:</li></ol>
233	the role of high-risk clones in the dissemination of antibiotic resistance. FEMS
234	Microbiol Rev 35:736-755
235	16. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B,
236	Huang X, Yu LF, Gu D, Ren H, Chen X, Lu L, He D, Zhou H, Liang Z, Liu JH, Shen J.
237	2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in
238	animals and human beings in China: a microbiological and molecular biological
239	study. Lancet Infect Dis 16:161-168.
240 241 242 243	<ol> <li>Lamb LM, Crandon JL, Nicolau DP. 2013. Pharmacokinetic and pharmacodynamic evaluation of P-873 versus <i>Klebsiella pneumoniae</i> in a neutropenic murine thigh infection model. Antimicrob Agents Chemother 57:1971-1973.</li> </ol>

Analog	MIC (µg/ml)							
	0.25	0.5	1	2	4	8	16	>16
RX-04A								
E. coli	1	8	14					
S. enterica			11					
K. pneumoniae		2	14	4				
E. cloacae		1	5	2				
Serratia spp.			1	2		1		
P. aeruginosa		1	4	4	10	1		
A. baumannii			3	4	1	2		
All	1	12	52	16	11	4		
RX-04B								
E. coli	1	6	15	1				
S. enterica			10	1				
K. pneumoniae		1	14	5				
E. cloacae			5	3				
Serratia spp.			1		2		1	
P. aeruginosa		1	3	4	7	2	2	1
A. baumannii			2	4	3	1		
All	1	8	50	18	12	3	3	1
RX-04C								
E. coli	1		12	10				
S. enterica				11				
K. pneumoniae		1	8	6	5			
E. cloacae			1	6	1			
<i>Serratia</i> spp.				1	2			1
P. aeruginosa		1		4	3	3	6	3
A. baumannii			3	1	2	4		
All	1	2	24	39	13	7	6	4

## 244 Table 1. Pyrrolocytosine MIC distributions by species, irrespective of resistance mechanism

RX-04D

All	1	5	47	15	13	11	4
A. baumannii			2	1	3	4	
P. aeruginosa			4		6	7	3
Serratia spp.			1	2			1
E. cloacae		1		5	2		
K. pneumoniae		2	11	5	2		
S. enterica			11				
E. coli	1	2	18	2			

246

247

#### **Table 2.** Geometric mean MIC (µg/ml) for different resistance groups 249

	n	RX-04A	RX-04B	RX-04C	RX-04D
E. coli, wild type	5	0.5	0.6	0.9	1.3
E. coli, carbapenemase	15 <sup>a</sup>	0.8	0.9	1.3	2.1
E. coli/Salmonella, mcr-1	14 <sup>b</sup>	1.0	1.1	2.0	2.0
<i>K. pneumoniae</i> , wild type	5	1.0	1.0	1.0	2.0
K. pneumoniae, carbapenemase	15 <sup>a</sup>	1.1	1.2	2.0	2.8
<i>E. cloacae</i> , wild type	4	1.0	1.2	1.7	3.4
<i>E. cloacae</i> , carbapenemase	4 <sup>c</sup>	1.2	1.4	2.4	4.8
Serratia spp., wild type	2	1,2 <sup>d</sup>	1,4 <sup>d</sup>	2,4 <sup>d</sup>	2,4 <sup>d</sup>
Serratia spp., carbapenemase	2 <sup>e</sup>	2,8 <sup>d</sup>	4,16 <sup>d</sup>	4,>16 <sup>d</sup>	4,16 <sup>d</sup>
<i>P. aeruginosa</i> , low efflux	5	1.5	1.7	3.5	5.3
P. aeruginosa, normal efflux/ wild type	5	2.6	3.0	7.0	11.3
<i>P. aeruginosa</i> , high efflux	5	2.6	3.0	7.0	6.1
P. aeruginosa, carbapenemase	5 <sup>f</sup>	3.5	6.7	5.7	12.7
A. baumannii, wild type	5	1.7	1.7	2.0	4.6
A. baumannii, OXA-23-positive	5	3.0	3.5	5.3	12.1

<sup>a</sup>Five isolates each with KPC, NDM and OXA-48-like enzymes 251

<sup>b</sup>11 S. enterica, 3 E. coli 252

<sup>c</sup>Two isolates with KPC enzymes and single strains with OXA-48 and NDM 253

<sup>d</sup> Single isolates with SME and OXA-48-like enzymes 254

<sup>e</sup> Since only two isolates were tested, actual MICs are shown, not the mean 255

<sup>f</sup>Two isolates with VIM, two with NDM carbapenemases, one with an IMP enzyme 256

Downloaded from http://aac.asm.org/ on June 26, 2018 by University of East Anglia

Accepted Manuscript Posted Online

257	FIGURE 1. RX-04 pyrrolocytosine structures
258	
259	
260	


- - 13

Downloaded from http://aac.asm.org/ on June 26, 2018 by University of East Anglia


ΝH


RX-04A

H <sub>2</sub> N




H <sub>3</sub> C •





0



Downloaded from http://aac.asm.org/ on June 26, 2018 by University of East Anglia

AAC